Rheumatoid Arthritis
Clinical experience shows anakinra beneficial for rheumatoid arthritis
Published in Medical Letter on the CDC and FDA, July 27th, 2003
"The recombinant interleukin-1 receptor antagonist, anakinra (Kineret; Amgen Inc, Thousand Oaks, CA), has been approved by the US Food and Drug Administration and the European Commission for the treatment of patients with active rheumatoid arthritis (RA). Approval was granted following the extensive evaluation of anakinra in five pivotal clinical trials that assessed its efficacy and safety in RA patients," scientists in the United States and Germany report.
"These studies have indicated that anakinra has a favorable risk-benefit profile, producing rapid and sustained...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- SARS
Array offered to government partners in effort to fight SARS - Diet and Nutrition
Strategies to boost women's multivitamin use fall short - Disease Associations
Women's childhood abuse linked to later poor health - AIDS and HIV Vaccine
Live recombinant vectors used for AIDS vaccine development - AIDS and HIV Vaccine
Need exists to define the protective antibody response for HIV-1 - Allergy Medicine
FDA says drug giant misleading consumers - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
